Abstract: The present disclosure provides a fusion protein comprising a TACI polypeptide and a use thereof, particularly a use for preventing or treating autoimmune diseases.

Abstract: A PVRIG binding protein and its medical uses. Specifically, an anti-PVRIG single-domain antibody and an anti-PVRIG and -TIGIT bispecific antibody, pharmaceutical compositions comprising the antibodies, a method for treating cancer, and pharmaceutical uses.

Abstract: Learning model task performance using a graph is described. A computing system can receive a prompt for performing a task using a learning model, where the task includes intermediate tasks. The computing system generates a graph to represent relationships between at least one term included in the prompt and additional terms associated with performing the task. The graph includes nodes corresponding to the at least one term and the additional terms and edges connecting the nodes. The edges correspond to the relationships between the at least one term and the additional terms. The computing system performs the intermediate tasks based on the graph to obtain a response to the prompt, where the intermediate tasks are associated with the additional terms. In some cases, the computing system removes one or more nodes from the graph responsive to results of the intermediate tasks. The computing system broadcasts the response to the prompt.

Abstract: Provided is an application of a JAK inhibitor in kidney disease. Specifically, provided is a use of a JAK inhibitor in the preparation of a drug for treating or preventing kidney disease.

Abstract: The present disclosure provides a method for screening and preparing an immunomodulator. The present disclosure further relates to a use of an immunosuppressant in the treatment of immune-related diseases.

Abstract: There is provided a method comprising receiving at least one measured signal characteristic from a user equipment, the user equipment being located at a user equipment location; comparing the at least one measured signal characteristic to at least one of a plurality of signal characteristics, each signal characteristic being associated with a respective measurement point; and determining, based on the comparing, a probability that the user equipment location is a first location.

Abstract: Provided are an anti-CD40 antibody, an antigen-binding fragment and a medical use thereof, as well as a pharmaceutical composition containing the anti-CD40 antibody or antigen-binding fragment thereof, and a method for treating and preventing disease, in particular a method for treating autoimmune disease.

Abstract: The present disclosure relates to a protein specifically binding to PD-1 and a pharmaceutical use thereof. Specifically, the present disclosure provides a protein specifically binding to PD-1, a protein specifically binding to PD-1/PVRIG/TIGIT, and a use thereof in the treatment of a disease (such as cancer).

Abstract: There is provided a method comprising receiving at least one measured signal characteristic from a user equipment, the user equipment being located at a user equipment location; comparing the at least one measured signal characteristic to at least one of a plurality of signal characteristics, each signal characteristic being associated with a respective measurement point; and determining, based on the comparing, a probability that the user equipment location is a first location.

Abstract: There is provided a method comprising receiving at least one measured signal characteristic from a user equipment, the user equipment being located at a user equipment location; comparing the at least one measured signal characteristic to at least one of a plurality of signal characteristics, each signal characteristic being associated with a respective measurement point; and determining, based on the comparing, a probability that the user equipment location is a first location.

Abstract: A drug conjugate of a glucocorticoid receptor agonist, and an application thereof in medicine. Specifically, the present invention relates to an antibody-drug conjugate as represented by formula (I): Ab-(L-D)k (I), wherein Ab is an antibody or an antigen-binding fragment thereof, L is a linker covalently linking Ab to D, k is 1 to 20, and D is as represented by formula (II-A) or (II-B). The groups in the formulas are as defined in the description. The antibody-drug conjugate can effectively treat autoimmune diseases.

Abstract: Provided are a complex of an anti-IL-4R antibody or an antigen-binding fragment thereof, and a medical use thereof. Specifically, provided are a complex of an antibody that specifically binds to IL-4R or an antigen-binding fragment thereof covalently linked to a toxin, a pharmaceutical composition comprising the complex, and a use thereof in the preparation of a drug for treating IL-4R-mediated diseases or disorders, especially a use in the preparation of an anti-cancer drug.

Abstract: Provided is an application of a JAK inhibitor in kidney disease. Specifically, provided is a use of a JAK inhibitor in the preparation of a drug for treating or preventing kidney disease.

Abstract: A PVRIG binding protein and its medical uses. Specifically, an anti-PVRIG single-domain antibody and an anti-PVRIG and -TIGIT bispecific antibody, pharmaceutical compositions comprising the antibodies, a method for treating cancer, and pharmaceutical uses.

Abstract: There is provided a method comprising receiving at least one measured signal characteristic from a user equipment, the user equipment being located at a user equipment location; comparing the at least one measured signal characteristic to at least one of a plurality of signal characteristics, each signal characteristic being associated with a respective measurement point; and determining, based on the comparing, a probability that the user equipment location is a first location.

Abstract: The present invention relates to an anti-CD40 antibody, an antigen binding fragment and a pharmaceutical use thereof. Heavy-chain constant regions of the anti-CD40 antibody and the antigen binding fragment thereof contain mutations. Due to the mutations, the anti-CD40 antibody loses the binding activity to Fc?RIII, and the binding of the anti-CD40 antibody and Fc?RIIB is enhanced, thereby losing the antibody-dependent cytotoxicity (ADCC) but improving Fc?RIIB-mediated antibody crosslinking. The mutations in the heavy-chain constant regions enhance the activation of CD40, and enhance the presentation of dendritic cells to antigens. The anti-CD40 antibody and the antigen binding fragment thereof can be used as anti-cancer drugs to treat CD40-mediated diseases or symptoms.